BCL9L and urinary bladder cancer: In bladder cancer, NAT10 knockdown specifically attenuated mRNA ac4C modification, impairing translation efficiency of BCL9L/SOX4/AKT1 and accelerating degradation of BCL9L/SOX4 transcripts (Wang et al., 2022a).